布鲁顿酪氨酸激酶抑制剂诱发心房颤动的机制研究进展  

Progress in mechanisms of Bruton′s tyrosine kinase inhibitor-induced atrial fibrillation

作　　者：高士豪(综述) 周涛(审校) GAO Shi-hao;ZHOU Tao(Zunyi Medical University,Guizhou 563000,China)

机构地区：[1]遵义医科大学,贵州563000 [2]贵州省人民医院心外科,贵阳550002

出　　处：《中国临床新医学》2023年第2期191-194,共4页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：国家自然科学基金项目(编号:82160056,81960050);贵州省科技计划项目(黔科合基础[2020]1Y293);贵州省卫生健康委员会科学技术基金项目(编号:gzwkj2021-193)。

摘　　要：布鲁顿酪氨酸激酶(BTK)抑制剂通过靶向抑制B细胞受体通路中的BTK阻碍B细胞相关恶性肿瘤的生长,但部分患者出现与药物相关的心房颤动(AF)。AF作为最常见的心律失常类型之一,研究其发生发展的机制在心脏相关疾病的治疗中十分重要。该文就BTK抑制剂诱导AF发生的机制研究进展作一综述。Bruton′s tyrosine kinase(BTK)inhibitors can inhibit the growth of B cell-related malignancies by targeting BTK in the B cell receptor pathway.However,during the use of BTK inhibitors,some patients develop drug-related atrial fibrillation(AF).AF is one of the most common types of arrhythmia,and it is very important to study the mechanisms of its occurrence and development in the treatment of heart-related diseases.This paper reviews the progress in mechanisms of BTK inhibitor-induced AF.

关 键 词：布鲁顿酪氨酸激酶抑制剂 心房颤动 发病机制 

分 类 号：R541[医药卫生—心血管疾病]